About Us
The Company
Founded in 2017, Op-T develops proprietary peptide-based therapeutics to treat chronic inflammation and immune dysregulation.
The name Op-T is derived from the company’s goal: to improve health by restoring optimal T-cell function without impairing normal immune responses.
Mission
Op-T’s mission is to enhance health by restoring optimal T-cell function without compromising normal immune responses – a goal supported by early data.
Key Personnel
Op-T’s executive team and members of its Board bring a wealth of biomedical product development experience, industry connections and medical innovation to the company.
Charlie Henry
Op-T Co-founder, CEO and Chairman
Brings 37 years of biomedical company development and management to his leadership of Op-T. Mr. Henry has worked within the diagnostic, device, and pharmaceutical sectors as a CEO, has raised capital through equity sales, negotiated complex licensing and distribution agreements with international and domestic partners, and led successful corporate sales to public and private acquirers
Dr. David H. Wagner
PhD., Co-founder, CSO and Op-T Director
Dr. Wagner has over 20 years of experience in medical research focusing on autoimmune diseases and biomarkers. Dr. Wagner is an Associate Professor of Medicine and Head of the Immunology Section of the Webb-Waring Center at the University of Colorado Anschutz Medical Campus.
Charlie Henry
Op-T Co-founder, CEO and Chairman
Brings 37 years of biomedical company development and management to his leadership of Op-T. Mr. Henry has worked within the diagnostic, device, and pharmaceutical sectors as a CEO, has raised capital through equity sales, negotiated complex licensing and distribution agreements with international and domestic partners, and led successful corporate sales to public and private acquirers